Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 4, 2017, Pages 280-290

  Raal, Frederick J ^a   Hovingh, G Kees ^b   Blom, Dirk ^c   Santos, Raul D ^d   Harada Shiba, Mariko ^e   Bruckert, Eric ^f   Couture, Patrick ^g   Soran, Handrean ^h   Watts, Gerald F ⁱ   Kurtz, Christopher ^j   Honarpour, Narimon ^j   Tang, Lihua ^j   Kasichayanula, Sree ^j   Wasserman, Scott M ^j   Stein, Evan A ^k  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g LAVAL UNIVERSITY   (Canada)

^h MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

ⁱ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^j AMGEN INC   (United States)

^k Metabolic and Atherosclerosis Research Center   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATINE KINASE; EVOLOCUMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUTRALIZING ANTIBODY; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ADD ON THERAPY; ADULT; AGED; ALLELE; APHERESIS; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FOLLOW UP; GENE MUTATION; HEADACHE; HEMATOMA; HOMOZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; INFLUENZA; INJECTION SITE CONTUSION; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE URTICARIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUTANT; OPEN STUDY; PAIN; PHASE 3 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; GENETICS; HOMOZYGOTE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; PROPROTEIN CONVERTASE 9; TREATMENT OUTCOME;

EID: 85012881693     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30044-X     Document Type: Article

References (28)

1. 1 Usifo, E, Leigh, SE, Whittall, RA, et al. Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet 76 (2012), 387–401.
2. 2 Sjouke, B, Kusters, DM, Kindt, I, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 36 (2015), 560–565.
3. 3 Cuchel, M, Bruckert, E, Ginsberg, HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 35 (2014), 2146–2157.
4. 4 Raal, FJ, Santos, RD, Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 223 (2012), 262–268.
5. 5 Marais, AD, Raal, FJ, Stein, EA, et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 197 (2008), 400–406.
6. 6 Raal, FJ, Pilcher, GJ, Illingworth, DR, et al. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis 135 (1997), 249–256.
7. 7 Gagné, C, Gaudet, D, Bruckert, E, for the Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105 (2002), 2469–2475.
8. 8 Stefanutti, C, Thompson, GR, Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. Curr Atheroscler Rep, 17, 2015, 465.
9. 9 Raal, FJ, Pilcher, GJ, Panz, VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 124 (2011), 2202–2207.
10. 10 Cuchel, M, Meagher, EA, du Toit, TH, et al., for the Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 381 (2013), 40–46.
11. 11 Raal, FJ, Santos, RD, Blom, DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL-cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375 (2010), 998–1006.
12. 12 Stein, EA, What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?. Curr Opin Endocrinol Diabetes Obes 23 (2016), 97–105.
13. 13 Raal, FJ, Honarpour, N, Blom, DJ, et al., for the TESLA investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 385 (2015), 341–350.
14. 14 Stein, EA, Honarpour, N, Wasserman, SM, Zu, F, Scott, R, Raal, FJ, Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 128 (2013), 2113–2120.
15. 15 Hobbs, HH, Brown, MS, Goldstein, JL, Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1 (1992), 445–466.
16. 16 Gordon, BR, Kelsey, SF, Bilheimer, DW, et al., for the Liposorber Study Group. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulphate cellulose adsorption system. Am J Cardiol 70 (1992), 1010–1016.
17. 17 Thompson, GR, Babir, M, Davies, D, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 208 (2010), 317–321.
18. 18 Raal, F, Scott, R, Somaratne, R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 126 (2012), 2408–2417.
19. 19 Raal, FJ, Stein, EA, Dufour, R, et al., for the RUTHERFORD-2 investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385 (2015), 331–340.
20. 20 Kastelein, JJ, Ginsberg, HN, Langslet, G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 36 (2015), 2996–3003.
21. 21 Raal, FJ, Giugliano, RP, Sabatine, MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J Am Coll Cardiol 63 (2014), 1278–1288.
22. 22 Gaudet, D, Watts, GF, Robinson, JG, et al. Effect of alirocumab on lipoprotein(a) over ≥1.5 years (from the phase 3 ODYSSEY Program. Am J Cardiol 119 (2017), 40–46.
23. 23 Raal, FJ, Giugliano, RP, Sabatine, MS, et al. PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res 57 (2016), 1086–1096.
24. 24 Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL-cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 376 (2010), 1670–1681.
25. 25 Kolansky, DM, Cuchel, M, Clark, BJ, et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol 102 (2008), 1438–1443.
26. 26 Stein, EA, Raal, FJ, Lipid-lowering drug therapy for CVD prevention: looking into the future. Curr Cardiol Rep, 17, 2015, 104.
27. 27 Gaudet, D, Gipe, DA, Khoury, É, Pordy, R, Sasiela, W, Chan, KC, Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, proof-of-concept study. Atherosclerosis 252 (2016), e254–e255 (abstr EAS16-0677).
28. 28 Ajufo, E, Cuchel, M, Recent developments in gene therapy for homozygous familial hypercholesterolemia. Curr Atheroscler Rep, 18, 2016, 22.